辛伐他汀对 2 型糖尿病合并颈动脉粥样硬化患者脂联素的抗炎作用。

Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis.

机构信息

Division of Endocrinology, The Affliated Drum Tower Hospital of Nanjing University, Nanjing 210008, China.

出版信息

Diab Vasc Dis Res. 2009 Oct;6(4):262-8. doi: 10.1177/1479164109339966.

DOI:10.1177/1479164109339966

PMID:20368220

Abstract

OBJECTIVE

Statins are extensively used for lowering LDL-cholesterol and reducing cardiovascular events. Recent studies have shown that statins have beneficial anti-inflammatory effects. We aimed to determine whether and how adipokines are regulated during statin treatment in type 2 diabetic patients.

METHOD

In this study,we investigated the changes of CRP and inflammation-related adipokines (SAA,IL-6,TNFalpha and adiponectin) in 23 type 2 diabetic patients with atherosclerosis who received statin therapy, and 20 diabetic patients with atherosclerosis and 14 diabetic patients without atherosclerosis who did not receive statin therapy for a period of three months.

RESULTS

By the end of the simvastatin treatment (40 mg, daily), LDL-cholesterol was decreased by 16.7% and HDL-cholesterol was increased by 31.9%. SAA, CRP, TNFalpha and IL-6 levels were decreased by 31.8%, 66.2%, 53.9% and 14%, respectively and adiponectin was increased by 59.6%, compared with the baseline levels. Interestingly, the decrease of SAA was positively correlated with that of LDL-cholesterol but negatively with HDL-cholesterol during statin treatment. Among the adipokines, the decrease of SAA was positively correlated with TNFalpha (r = 0.50, p = 0.016).

CONCLUSION

The results suggest that adipokines may be differentially regulated and independent of cholesterol changes and that adipokines may be a mediator, and the adipose tissue may be a target of statins' anti-inflammatory effect.

摘要

目的

他汀类药物广泛用于降低 LDL 胆固醇和减少心血管事件。最近的研究表明，他汀类药物具有有益的抗炎作用。我们旨在确定在 2 型糖尿病患者中他汀类药物治疗期间是否以及如何调节脂肪因子。

方法

在这项研究中，我们调查了 23 例接受他汀类药物治疗的伴有动脉粥样硬化的 2 型糖尿病患者、20 例伴有动脉粥样硬化但未接受他汀类药物治疗的糖尿病患者和 14 例不伴有动脉粥样硬化但未接受他汀类药物治疗的糖尿病患者的 CRP 和炎症相关脂肪因子（SAA、IL-6、TNFalpha 和脂联素）的变化。

结果

在辛伐他汀治疗结束时（40mg，每日），LDL 胆固醇降低 16.7%，HDL 胆固醇升高 31.9%。SAA、CRP、TNFalpha 和 IL-6 水平分别降低 31.8%、66.2%、53.9%和 14%，脂联素升高 59.6%，与基线水平相比。有趣的是，在他汀类药物治疗期间，SAA 的降低与 LDL 胆固醇的降低呈正相关，与 HDL 胆固醇的降低呈负相关。在这些脂肪因子中，SAA 的降低与 TNFalpha 呈正相关（r = 0.50，p = 0.016）。